1. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir
- Author
-
Pietro Andreone, Anna S.F. Lok, Erwin Sablon, Carmela Cursaro, Munira Hussain, Evelien Libbrecht, Scott K. Fung, Hussain M., Fung S., Libbrecht E., Sablon E., Cursaro C., Andreone P., and Lok A.S.
- Subjects
Microbiology (medical) ,Hepatitis B virus ,Genes, Viral ,Mutant ,Organophosphonates ,Drug resistance ,Biology ,In Vitro Techniques ,medicine.disease_cause ,Antiviral Agents ,Polymerase Chain Reaction ,Sensitivity and Specificity ,Hepatitis B, Chronic ,Virology ,Drug Resistance, Viral ,medicine ,Adefovir ,Humans ,Line Probe Assay ,Mutation ,Base Sequence ,Adenine ,fungi ,Lamivudine ,food and beverages ,virus diseases ,RNA-Directed DNA Polymerase ,Hepatitis B ,medicine.disease ,Molecular biology ,digestive system diseases ,DNA, Viral ,DNA Probes ,medicine.drug - Abstract
The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.
- Published
- 2006